Healthcare Distributors

Harrow Health Pref Share HROWM 11.875 12/31/27

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

HROW

HROWL

HROWM

Harrow Inc. announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for treating vernal keratoconjunctivitis in children. This steroid-sparing therapy aims to reduce corticosteroid dependence and associated risks like glaucoma. CEO Mark Baum highlighted this as a key step in Harrow's ophthalmology strategy, with William Blair noting it serves as supplemental revenue while strengthening the company's portfolio.

benzinga_article

Harrow

Harrow Health Pref Share HROWL 8.625 04/30/26

Jazz Pharma

Clover Health Investments

Harrow Adds Another Piece To Ophthalmology Strategy

ARKG

LABU

Harrow Inc (NASDAQ:HROW) reported Q1 2026 revenues of $44.2 million, with an adjusted EBITDA of -$12.7 million, impacted by an $8 million gross-to-net issue with its product Vivi. The company has expanded its sales force to drive growth and reaffirmed its full-year revenue guidance of $350 million to $365 million, anticipating strong performance in the second half due to new product launches and improved pricing strategies. Demand for core products remains strong, indicating sustainable market share capture and potential for profitable revenue growth.

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Health Care Select Sector SPDR

iShares US Pharma

Ark Genomic Revolution ETF

SPDR Pharmac

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

VG Health

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Transcript: Harrow Q1 2026 Earnings Conference Call

Harrow shares are trading lower after the company reported worse-than-expected Q1 financial results.

UXIN

ETON

FSUN

The U.S. market has risen 3.1% in the past week and 27% over the last year, with earnings expected to grow by 16% annually. Growth companies with high insider ownership are highlighted as attractive investments. Top companies include Uxin (35.6% insider ownership, 74.1% earnings growth) and Eton Pharmaceuticals (15% insider ownership, 29.8% earnings growth). ASP Isotopes and FirstSun Capital Bancorp also show strong growth potential. The article emphasizes the importance of insider ownership as a confidence indicator and provides insights into various companies' financial forecasts and market positions.

Simplywall

Uxin

Eton Pharmaceuticals

Firstsun Capital Bancorp

Invesco Nasdaq Biotechnology ETF

iShares Global Healthcare

April 2026's Top Growth Companies With Strong Insider Ownership

LogiCare3PL Selected as Distribution Partner by Harrow | HROW Stock News

StockTitan

LogiCare3PL Selected as Distribution Partner by Harrow | HROW Stock News

Harrow Health Expands Senior Notes Offering for Growth

Tip Ranks

Harrow Health Expands Senior Notes Offering for Growth

Opaleye Management sold nearly 200,000 shares of Harrow after a disappointing earnings report, reducing its stake to close to 10%. Despite a recent 33% decline in share price, Harrow's stock has gained 26.9% over the past year. The sale, combined with the issuance of $50 million in high-interest debt, raises concerns about execution risk and profitability. Investors should monitor Harrow's ability to convert its product pipeline into cash flow and watch insider trading activity for further insights.

Opaleye Trims Harrow Stake After Earnings Miss While Debt Risk Rises

Harrow (Nasdaq: HROW) has priced a private offering of $50 million in senior unsecured notes due 2030 at an interest rate of 8.625%. The notes will mature on September 15, 2030, and the net proceeds will be allocated for general corporate purposes, including product launches and strategic opportunities. The offering is set to close on March 27, 2026. After hours, HROW shares rose by 0.48% to $35.37.

Harrow prices $50M senior unsecured notes due 2030 at 8.625%

Harrow Health Prices $50 Million Senior Notes Offering

Harrow Health Prices $50 Million Senior Notes Offering

Harrow Health Pref Share HROWM 11.875 12/31/27(HROWM.US)

Harrow Adds Another Piece To Ophthalmology Strategy

Transcript: Harrow Q1 2026 Earnings Conference Call

Harrow shares are trading lower after the company reported worse-than-expected Q1 financial results.

April 2026's Top Growth Companies With Strong Insider Ownership

LogiCare3PL Selected as Distribution Partner by Harrow | HROW Stock News